Study Shows Pfizer COVID Shot Has 37 Percent Higher Risk of Mortality Than Moderna Shot
According to a new study, adults who received the Pfizer Comirnaty COVID-19 shot were more likely to die than adults who had the Moderna Spikevax COVID-19 shot. The study looked at 9.2 million adults living in Florida who received either Comirnaty or Spikevax within six weeks, from December 2020 through January 2021. Half of the […]
FDA, CDC Halt Use of Chikungunya Vaccine in Adults 60+ After Two Deaths Reported
On May 9, 2025, the U.S. Food and Drug Administration (FDA) and the U.S. Centers for Disease Control and Prevention (CDC) recommended a temporary pause in the use of Ixchiq, a live virus vaccine designed to prevent chikungunya virus infection, in adults aged 60 years and older. The recommendation follows reports of serious post-marketing adverse […]
ACIP Reports on First “Do-It-Yourself at Home” Nasal Flu Shot
In September 2024, the U.S. Food and Drug Administration (FDA) licensed the first of its kind live attenuated nasal spray influenza vaccine to be administered at home during the 2024-2025 “flu season.” Adults up to the 49 years of age are eligible to self-administer the FluMist Home vaccine or give it to their children aged […]
CDC’s ACIP Forms Workgroup to Back New Lyme Disease Vaccine and Monoclonal Antibody Products
At an Apr.15-16, 2025 meeting of the U.S. Centers for Disease and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP), it was announced that a workgroup had been formed to further development of a new vaccine for Lyme disease. The first session of the new group will take place in May with a presentation scheduled […]
HHS Halts Funding for Development of Next-Generation COVID Biologics
The U.S. Department of Health and Human Services (DHHS) has stopped U.S. government funding for the development of next-generation COVID-19 biologics by two companies, GeoVax, Inc. of Atlanta, Georgia and CastleVax, Inc. of New York. The project had been funded by Project NextGen, a Biden administration initiative under the U.S. Center for the Biomedical Advanced […]
Guillain-Barré Syndrome Warning Added to Shingrix Vaccine in Australia
In February 2024, Australia’s Therapeutic Goods Administration (TGA), the country’s national regulatory authority for drugs and, initiated an investigation into a potential association between GSK plc’s Shingrix shingles vaccine, Guillain-Barré syndrome (GBS), which causes inflammation and damage to the nerves, that may include paralysis.1 The investigation was prompted by two reports of GBS following Shingrix […]